跳到正文
原文
Moderna· @moderna_tx · X·· 13 天前精选AI 评分47
AI 导读

Moderna宣布,其针对邦迪布焦埃博拉病毒(BDBV)的在研mRNA疫苗mRNA-1469,基于临床前和1期临床数据获得的积极结果,被推荐在刚果民主共和国推进至2/3期疗效研究。

推荐理由

原文说明了mRNA-1469推进至2/3期临床所依据的早期数据,读者可据此了解该疫苗的研发阶段。

正文

Today we announced that mRNA-1469, our investigational mRNA vaccine candidate against Bundibugyo ebolavirus (BDBV), has been recommended to advance into a Phase 2/3 efficacy study in the Democratic Republic of the Congo (DRC), supported by encouraging preclinical and Phase 1 clinical data.

Read more: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/moderna-advances-investigational-bundibugyo-ebolavirus-vaccine-toward-1246308

来源:Moderna · x.com